Literature DB >> 34544816

Epidemiology, Clinical Features, and Outcome in a Cohort of Adolescents With Cerebral Venous Thrombosis.

Julia Devianne1, Nicolas Legris1, Isabelle Crassard1, Celine Bellesme1, Yannick Bejot1, Celine Guidoux1, Fernando Pico1, David Germanaud1, Michael Obadia1, Diana Rodriguez1, Philippe Tuppin1, Manoelle Kossorotoff1, Christian Denier2.   

Abstract

BACKGROUND AND OBJECTIVES: We aimed to analyze the epidemiologic, clinical, and paraclinical features of adolescents with cerebral venous thrombosis (CVT) and its therapeutic management and outcome.
METHODS: This multicenter retrospective cohort included patients 10 to 18 years of age hospitalized for a first episode of CVT in 2 French regions between 1999 and 2019. The number of cases was compared to the number recorded by the French health insurance system. The CVT registry of the Lariboisière hospital allowed comparisons with adults.
RESULTS: One hundred two patients were included (52.9% female; median age 15.1 years). Estimated incidence was 0.37 to 0.38 per 100,000 adolescents per year; 45.5% of patients presented with focal deficits or seizures or in a coma. Male patients were younger than female patients (14.2 vs 15.6 years; p < 0.01) and more often admitted to intensive care (52.1% vs 24.1%; p = 0.0,035). The lateral sinus was the most common CVT location (72.3%), and 29.4% of adolescents had associated venous infarction or hematoma. Most patients (94.1%) received anticoagulation. Treatment also included an endovascular procedure (2.9%), decompressive craniectomy (4.9%), and CSF shunt (6.9%). The most frequently identified CVT-associated condition was local infection in male (18.6%) and systemic disease in female (14.8%; p < 0.001) patients. The proportion of CVTs in adolescents without an identified associated condition or risk factor was low (1.9% vs 11.4% in adults; p < 0.002). Adverse outcome at 1 year was more frequent than in adults (33.3% vs 11.8%; p = 0.0,001). DISCUSSION: CVT in adolescents is rare and complex with specific epidemiology, including differences in clinical presentation and associated conditions between sexes, and more severe outcomes than in adults. Careful specialized management and follow-up are therefore recommended.
© 2021 American Academy of Neurology.

Entities:  

Mesh:

Year:  2021        PMID: 34544816      PMCID: PMC8601207          DOI: 10.1212/WNL.0000000000012828

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study.

Authors:  Sharon Devasagayam; Ben Wyatt; James Leyden; Timothy Kleinig
Journal:  Stroke       Date:  2016-07-19       Impact factor: 7.914

2.  Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review.

Authors:  Emmanuel Cognat; Isabelle Crassard; Christian Denier; Kouroche Vahedi; Marie-Germaine Bousser
Journal:  Int J Stroke       Date:  2011-10-21       Impact factor: 5.266

Review 3.  Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Gustavo Saposnik; Fernando Barinagarrementeria; Robert D Brown; Cheryl D Bushnell; Brett Cucchiara; Mary Cushman; Gabrielle deVeber; Jose M Ferro; Fong Y Tsai
Journal:  Stroke       Date:  2011-02-03       Impact factor: 7.914

4.  Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management.

Authors:  Khaled M Ghanem; Raghida M Dhayni; Carol Al-Aridi; Nidale Tarek; Hani Tamim; Anthony K C Chan; Raya Saab; Miguel R Abboud; Hassan El-Solh; Samar A Muwakkit
Journal:  Pediatr Blood Cancer       Date:  2017-06-29       Impact factor: 3.167

5.  Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study.

Authors:  Mahendranath D Moharir; Manohar Shroff; Derek Stephens; Ann-Marie Pontigon; Anthony Chan; Daune MacGregor; David Mikulis; Margaret Adams; Gabrielle deVeber
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

6.  European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology.

Authors:  J M Ferro; M-G Bousser; P Canhão; J M Coutinho; I Crassard; F Dentali; M di Minno; A Maino; I Martinelli; F Masuhr; D Aguiar de Sousa; J Stam
Journal:  Eur J Neurol       Date:  2017-08-20       Impact factor: 6.089

7.  Neonatal arterial ischemic stroke and cerebral sinovenous thrombosis are more commonly diagnosed in boys.

Authors:  Meredith R Golomb; Paul T Dick; Daune L MacGregor; Rosalind Curtis; Marianne Sofronas; Gabrielle A deVeber
Journal:  J Child Neurol       Date:  2004-07       Impact factor: 1.987

8.  Cerebral venous thrombosis in children: a multifactorial origin.

Authors:  Christine Heller; Achim Heinecke; Ralf Junker; Ralf Knöfler; Andrea Kosch; Karin Kurnik; Rosemarie Schobess; Arnold von Eckardstein; Ronald Sträter; Barbara Zieger; Ulrike Nowak-Göttl
Journal:  Circulation       Date:  2003-08-25       Impact factor: 29.690

9.  Cerebral venous and sinus thrombosis in women.

Authors:  Jonathan M Coutinho; José M Ferro; Patrícia Canhão; Fernando Barinagarrementeria; Carlos Cantú; Marie-Germaine Bousser; Jan Stam
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

10.  Misdiagnosis of Cerebral Vein Thrombosis in the Emergency Department.

Authors:  Ava L Liberman; Gino Gialdini; Ekaterina Bakradze; Abhinaba Chatterjee; Hooman Kamel; Alexander E Merkler
Journal:  Stroke       Date:  2018-04-25       Impact factor: 7.914

View more
  2 in total

1.  Predictive Factors for Early-Onset Seizures in Patients With Cerebral Venous Sinus Thrombosis.

Authors:  Shuwen Mu; Jun Li; Kunzhe Lin; Yi Fang; Feng Lin; Ziqi Li; Yongjun Xu; Shousen Wang
Journal:  Front Neurol       Date:  2022-03-29       Impact factor: 4.003

Review 2.  Endovascular Treatment of Intracranial Vein and Venous Sinus Thrombosis-A Systematic Review.

Authors:  Philipp Bücke; Victoria Hellstern; Alexandru Cimpoca; José E Cohen; Thomas Horvath; Oliver Ganslandt; Hansjörg Bäzner; Hans Henkes
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.